Skip to main content

INEX Innovate receives European CE-IVD Certification for its OvaCis® Rapid Test

By May 11, 2022May 30th, 2022No Comments

The team at INEX Innovate is proud to announce the attainment of CE marking for it’s 𝐎𝐯𝐚𝐂𝐢𝐬® 𝐑𝐚𝐩𝐢𝐝 𝐓𝐞𝐬𝐭 as covered by industry publication BioSpace.

Slated to launch in the EU and Southeast Asian markets by the end of 2022, 𝐎𝐯𝐚𝐂𝐢𝐬® is a first of its kind point-of-care (POCT) test that discriminates benign from malignant ovarian cysts screens ovarian cysts for malignancy in an operating theatre setting.

𝐎𝐯𝐚𝐂𝐢𝐬® 𝐑𝐚𝐩𝐢𝐝 𝐓𝐞𝐬𝐭 empowers surgeons to make fast informed evidence-based decisions within the confines of a high pressure surgical environment by identifying a protein biomarker (haptoglobin) evenly distributed in ovarian cysts fluid to determine if the cysts are benign or malignant, providing results in 15 minutes – significantly reducing surgical procedure time.

Leave a Reply

About the Technology

A simple sample collection using the common HPV swab is taken and the DNA is extracted. The extracted DNA undergoes bisulfite conversion before an accurate method of screening through real-time PCR analyses. The bisulfite conversion functions by converting unmethylated Cytosine nucleotides to Uracil, which is then converted to Thymine by PCR. Conversely, the methylation mark protects the methylated Cytosine nucleotides from being converted to Uracil.